Adam Stępień

The relationship between plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis

Andrzej Ledwoż yw, Jerzy Michalak, Adam Stępień et al. · Clinica Chimica Acta · 1986 · 515 citations

Biochemistry, Cardiovascular Disease, Physiology +11

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism

Bogdan Brodacki, Jacek Staszewski, Beata Toczyłowska et al. · Neuroscience Letters · 2008 · 308 citations

Systemic Diseases, Immunology, Immune Dysregulation +18

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

Ashkan Shoamanesh, Hardi Mundl, Eric E. Smith et al. · The Lancet · 2022 · 181 citations · Full text

Thrombosis, Cardiovascular Disease, Ischemic Stroke +14

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 173 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +5